Bristol Myers Squibb stock faces a key October 29 results date

Published on 10/04/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock last closed at USD 61.15 on October 2, 2026, 10.9 percent below its 52-week high. Q2 revenue reached USD 12.97 billion.

Bristol-Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock faces a key October 29 results date, with the shares closing at USD 61.15 on the NYSE on October 2, 2026. The price was 10.9 percent below the 52-week high of USD 68.64, while the company heads into its next report after a strong second quarter.

October 29 sets the next test

According to Bristol Myers Squibb in a September 18, 2026, release, third-quarter results will be published on October 29, 2026, followed by an investor call at 8:00 a.m. ET. That date puts the company's newer medicines and pipeline progress against the continuing pressure from mature products and patent expirations.

The most recent reported quarter offers a clear benchmark. MarketBeat reported that second-quarter revenue was USD 12.97 billion, up 5.7 percent from the prior year, while quarterly EPS reached USD 2.04 against a USD 1.60 consensus estimate. Revenue also exceeded the USD 11.74 billion estimate.

Analysts see room above USD 61.15

MarketBeat lists a Moderate Buy consensus from 25 brokerages, including 13 Buy ratings, 10 Hold ratings, one Sell rating and one Strong Buy rating. The average 12-month price target is USD 67.06, with recent targets from USD 64 to USD 82, placing the average target 9.7 percent above the October 2 price.

The range of views is important because the company is balancing current earnings strength with a longer-term replacement challenge. MarketBeat noted that Piper Sandler raised its target from USD 75 to USD 82 on September 16, 2026, while JPMorgan raised its target from USD 67 to USD 73 on July 31, 2026.

Stock remains below its yearly high

Bristol Myers Squibb shares closed at USD 61.15 on October 2, 2026, up USD 0.32, or 0.53 percent, from the prior close. The NYSE-listed company had a market capitalization of USD 124.9 billion and a 52-week range of USD 42.52 to USD 68.64, leaving the October 29 report as the next concrete checkpoint for the stock.